In April 2005, Affymetrix will make ArrayAssist Lite available to its existing GeneChip customers via the Internet and will also begin pre-installing the software on new GeneChip workstation desktops. Through an easy-to-use interface and tightly integrated workflow, ArrayAssist Lite will enable the application of industry-leading statistical algorithms and generation of standard Affymetrix-format data files and reports. In its first release, ArrayAssist Lite will support RMA, GC-RMA, MAS5, and also PLIER, a new advanced signal estimator developed by Affymetrix statisticians. Affymetrix customers will also be given the option of upgrading to Stratagene's ArrayAssist software, which provides advanced downstream analysis capabilities such as gene clustering, pattern detection, and interactive visualizations.
"ArrayAssist Lite software will provide highly accurate, precise and sensitive methods needed to support expression research," said Jason Goncalves, General Manager of Stratagene's software solutions business. "We've placed these capabilities in a software tool designed for life scientists, and the result will be better quality data to accelerate biological discovery and validation."
"We are very pleased to announce this expansion of our longstanding relationship with Stratagene," said Steve Lincoln, Vice-President of Informatics at Affymetrix. "The combination of our GeneChip platform and the ArrayAssist softw are makes the industry-leading methods for measuring gene expression on a genomic-scale available to an ever broadening community of life scientists."
As part of the agreement, Stratagene has joined the community of Affymetrix partners developing methods for next-generation gene expression microarrays. "Affymetrix' tiling arrays are revolutionizing functional analysis," said Dr. Joseph A. Sorge, Chairman and CEO of Stratagene. "We believe that our technology will provide key functionality needed to support important genomic studies. In addition, we're very excited to join Affymetrix' consortium of developers in an effort to bring to market breakthrough gene expression microarray technology. By partnering with other thought leaders in our field, we believe we have the opportunity to position our technology as a standard for expression analysis."